Cargando…

Characterization of genomic alterations in Chinese colorectal cancer patients with liver metastases

BACKGROUND: The exploration of genomic alterations in Chinese colorectal liver metastasis (CRLM) is limited, and corresponding genetic biomarkers for patient’s perioperative management are still lacking. This study aims to understand genome diversification and complexity that developed in CRLM. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hong-Wei, Yan, Xiao-Luan, Wang, Li-Jun, Zhang, Meng-Huan, Yang, Chun-He, Wei-Liu, Jin, Ke-Min, Bao, Quan, Li, Juan, Wang, Kun, Xing, Bao-Cai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287676/
https://www.ncbi.nlm.nih.gov/pubmed/34281583
http://dx.doi.org/10.1186/s12967-021-02986-0
_version_ 1783723956450099200
author Wang, Hong-Wei
Yan, Xiao-Luan
Wang, Li-Jun
Zhang, Meng-Huan
Yang, Chun-He
Wei-Liu
Jin, Ke-Min
Bao, Quan
Li, Juan
Wang, Kun
Xing, Bao-Cai
author_facet Wang, Hong-Wei
Yan, Xiao-Luan
Wang, Li-Jun
Zhang, Meng-Huan
Yang, Chun-He
Wei-Liu
Jin, Ke-Min
Bao, Quan
Li, Juan
Wang, Kun
Xing, Bao-Cai
author_sort Wang, Hong-Wei
collection PubMed
description BACKGROUND: The exploration of genomic alterations in Chinese colorectal liver metastasis (CRLM) is limited, and corresponding genetic biomarkers for patient’s perioperative management are still lacking. This study aims to understand genome diversification and complexity that developed in CRLM. METHODS: A custom-designed IDT capture panel including 620 genes was performed in the Chinese CRLM cohort, which included 396 tumor samples from metastatic liver lesions together with 133 available paired primary tumors. RESULTS: In this Chinese CRLM cohort, the top-ranked recurrent mutated genes were TP53 (324/396, 82%), APC (302/396, 76%), KRAS (166/396, 42%), SMAD4 (54/396, 14%), FLG (52/396, 13%) and FBXW7 (43/396, 11%). A comparison of CRLM samples derived from left- and right-sided primary lesions confirmed that the difference in survival for patients with different primary tumor sites could be driven by variations in the transforming growth factor β (TGF-β), phosphatidylinositol 3-kinase (PI3K) and RAS signaling pathways. Certain genes had a higher variant rate in samples with metachronous CRLM than in samples with simultaneous metastasis. Overall, the metastasis and primary tumor samples displayed highly consistent genomic alterations, but there were some differences between individually paired metastases and primary tumors, which were mainly caused by copy number variations. CONCLUSION: We provide a comprehensive depiction of the genomic alterations in Chinese patients with CRLM, providing a fundamental basis for further personalized therapy applications. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-021-02986-0.
format Online
Article
Text
id pubmed-8287676
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82876762021-07-19 Characterization of genomic alterations in Chinese colorectal cancer patients with liver metastases Wang, Hong-Wei Yan, Xiao-Luan Wang, Li-Jun Zhang, Meng-Huan Yang, Chun-He Wei-Liu Jin, Ke-Min Bao, Quan Li, Juan Wang, Kun Xing, Bao-Cai J Transl Med Research BACKGROUND: The exploration of genomic alterations in Chinese colorectal liver metastasis (CRLM) is limited, and corresponding genetic biomarkers for patient’s perioperative management are still lacking. This study aims to understand genome diversification and complexity that developed in CRLM. METHODS: A custom-designed IDT capture panel including 620 genes was performed in the Chinese CRLM cohort, which included 396 tumor samples from metastatic liver lesions together with 133 available paired primary tumors. RESULTS: In this Chinese CRLM cohort, the top-ranked recurrent mutated genes were TP53 (324/396, 82%), APC (302/396, 76%), KRAS (166/396, 42%), SMAD4 (54/396, 14%), FLG (52/396, 13%) and FBXW7 (43/396, 11%). A comparison of CRLM samples derived from left- and right-sided primary lesions confirmed that the difference in survival for patients with different primary tumor sites could be driven by variations in the transforming growth factor β (TGF-β), phosphatidylinositol 3-kinase (PI3K) and RAS signaling pathways. Certain genes had a higher variant rate in samples with metachronous CRLM than in samples with simultaneous metastasis. Overall, the metastasis and primary tumor samples displayed highly consistent genomic alterations, but there were some differences between individually paired metastases and primary tumors, which were mainly caused by copy number variations. CONCLUSION: We provide a comprehensive depiction of the genomic alterations in Chinese patients with CRLM, providing a fundamental basis for further personalized therapy applications. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-021-02986-0. BioMed Central 2021-07-19 /pmc/articles/PMC8287676/ /pubmed/34281583 http://dx.doi.org/10.1186/s12967-021-02986-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Hong-Wei
Yan, Xiao-Luan
Wang, Li-Jun
Zhang, Meng-Huan
Yang, Chun-He
Wei-Liu
Jin, Ke-Min
Bao, Quan
Li, Juan
Wang, Kun
Xing, Bao-Cai
Characterization of genomic alterations in Chinese colorectal cancer patients with liver metastases
title Characterization of genomic alterations in Chinese colorectal cancer patients with liver metastases
title_full Characterization of genomic alterations in Chinese colorectal cancer patients with liver metastases
title_fullStr Characterization of genomic alterations in Chinese colorectal cancer patients with liver metastases
title_full_unstemmed Characterization of genomic alterations in Chinese colorectal cancer patients with liver metastases
title_short Characterization of genomic alterations in Chinese colorectal cancer patients with liver metastases
title_sort characterization of genomic alterations in chinese colorectal cancer patients with liver metastases
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287676/
https://www.ncbi.nlm.nih.gov/pubmed/34281583
http://dx.doi.org/10.1186/s12967-021-02986-0
work_keys_str_mv AT wanghongwei characterizationofgenomicalterationsinchinesecolorectalcancerpatientswithlivermetastases
AT yanxiaoluan characterizationofgenomicalterationsinchinesecolorectalcancerpatientswithlivermetastases
AT wanglijun characterizationofgenomicalterationsinchinesecolorectalcancerpatientswithlivermetastases
AT zhangmenghuan characterizationofgenomicalterationsinchinesecolorectalcancerpatientswithlivermetastases
AT yangchunhe characterizationofgenomicalterationsinchinesecolorectalcancerpatientswithlivermetastases
AT weiliu characterizationofgenomicalterationsinchinesecolorectalcancerpatientswithlivermetastases
AT jinkemin characterizationofgenomicalterationsinchinesecolorectalcancerpatientswithlivermetastases
AT baoquan characterizationofgenomicalterationsinchinesecolorectalcancerpatientswithlivermetastases
AT lijuan characterizationofgenomicalterationsinchinesecolorectalcancerpatientswithlivermetastases
AT wangkun characterizationofgenomicalterationsinchinesecolorectalcancerpatientswithlivermetastases
AT xingbaocai characterizationofgenomicalterationsinchinesecolorectalcancerpatientswithlivermetastases